The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with pan-Hsp90 Inhibition
- 11 January 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (3), 1545-1557
- https://doi.org/10.1021/acs.jmedchem.0c01700
Abstract
The 90 kD heat shock proteins (Hsp90) are molecular chaperones that are responsible for the folding of select proteins, many of which are directly associated with cancer progression. Consequently, inhibition of the Hsp90 protein folding machinery results in a combinatorial attack on numerous oncogenic pathways. Seventeen small-molecule inhibitors of Hsp90 have entered clinical trials for the treatment of cancer, all of which bind the Hsp90 N-terminus and exhibit pan-inhibitory activity against all four Hsp90 isoforms, which may lead to adverse effects. The development of Hsp90 isoform-selective inhibitors represents an alternative approach toward the treatment of cancer and may limit some of these detriments. Described herein, is a structure-based approach to develop isoform-selective inhibitors of Hsp90β, which induces the degradation of select Hsp90 clients without concomitant induction of Hsp90 levels. Together, these initial studies support the development of Hsp90β-selective inhibitors as a method for overcoming the detriments associated with pan-inhibition.Keywords
Funding Information
- Division of Chemistry (0320648)
- National Cancer Institute (CA213566)
- National Center for Research Resources (S10RR024664)
- NIH Office of the Director (S10OD016360)
This publication has 44 references indexed in Scilit:
- Development of a Grp94 inhibitorJournal of the American Chemical Society, 2012
- The hERG Channel Is Dependent upon the Hsp90α Isoform for Maturation and TraffickingMolecular Pharmaceutics, 2012
- Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancersBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2012
- Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?Clinical Cancer Research, 2012
- Thermodynamics of radicicol binding to human Hsp90 alpha and beta isoformsBiophysical Chemistry, 2010
- Targeting the dynamic HSP90 complex in cancerNature Reviews Cancer, 2010
- Hsp90 and co‐chaperones twist the functions of diverse client proteinsPeptide Science, 2009
- Inhibitors of the heat shock response: Biology and pharmacologyFEBS Letters, 2007
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisOncogene, 2007
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987